Recombinant activated coagulation factor VII (rFVIIa; eptacog alfa activated; NovoSeven®[Novo Nordisk A/S, Bagsværd, Denmark]) has been used as a bypassing agent in hemophilia A or B patients with inhibitors since its approval in Europe in 1996.1rFVIIa bypassing treatment results in hemostasis by binding to the surface of activated platelets, which in turn leads to initiation of factor X (FX) activation and subsequent thrombin generation.2The first formulation of rFVIIa required storage at 2 to 8°C. Here, F10 is linked to hemophilia A.